SCHEMBL7076288

SCHEMBL7076288

CCOC(=O)/C=C1/CCCc2cc(OC)ccc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DRD1 P21728 5/20 0.42
DRD2 P14416 4/20 0.42
DRD5 P21918 4/20 0.42
DRD3 P35462 4/20 0.42
DRD4 P21917 3/20 0.42
NPC1 O15118 2/20 0.41
POLB P06746 2/20 0.41
RAB9A P51151 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
ESR2 Q92731 1/20 0.40
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7076293 1.00 MAPT (0.43) MAPTALDH1A1L3MBTL1DRD1DRD2
SCHEMBL7075532 0.95 MAPT (0.43) MAPTALDH1A1L3MBTL1DRD1DRD2
SCHEMBL7075529 0.95 MAPT (0.43) MAPTALDH1A1L3MBTL1DRD1DRD2
SCHEMBL13221540 0.93 DRD2 (0.43) DRD1DRD2DRD5DRD3DRD4
SCHEMBL7131312 0.93 DRD2 (0.43) DRD1DRD2DRD5DRD3DRD4
SCHEMBL7076510 0.93 DRD2 (0.43) DRD1DRD2DRD5DRD3DRD4
SCHEMBL14761632 0.88 MTNR1A (0.43) MAPTALDH1A1DRD1DRD2DRD5
SCHEMBL7073014 0.88 MTNR1A (0.43) MAPTALDH1A1DRD1DRD2DRD5
SCHEMBL16510284 0.88 MTNR1A (0.43) MAPTALDH1A1DRD1DRD2DRD5
SCHEMBL8514303 0.79 NQO2 (0.53) MAPTNPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin WYETH (US) 2003-06-12 US disclosed
US-6429214-B1 INHIBITORS OF BONE RESORPTION WYETH 2002-08-06 US disclosed
EP-1198231-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-24 EP disclosed
WO-2001007036-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin ITGAV, ITGB2, ITGB3 MAPT 4836/4885ALDH1A1 1467/4885L3MBTL1 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.